Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I)

Antiretroviral therapy (ART) has transformed HIV from a deadly disease into a lifelong infection that can be controlled. Nevertheless, in the majority of people living with HIV (PWH), discontinuation of ART results in viral rebound due to a latent proviral reservoir. Rarely, individuals known as post-treatment controllers (PTC) demonstrate prolonged viral control even after ceasing ART. Investigating the underlying mechanisms driving this sustained viral control has been a goal for the HIV research community. However, previous studies have been hindered by the scarcity of PTC cases, thereby restricting the potential for associative and translational research. Consequently, the aim of this study is to collect and meta-analyse the data from prior trials where PTC have been identified, as well as to retrospectively identify PTC from the routine care outside trials in a multicentre, multinational study called EU2Control. The aggregated clinical data, and the already collected material from trials where PWH consented for use in additional studies on HIV, will be analyzed with the goal to identify predictive biomarkers for sustained viral control. This study will be part of the research line on HIV cure from an ongoing collaborative consortium (EU2Cure). The first phase of this research line involves a retrospective cohort for meta-analysis and establishment of a biobank.

NCT Number	NCT07692295
Lead Sponsor	Erasmus Medical Center Collaborators: EU2Cure consortium, Radboud University Medical Center, European Aids Treatment Group (EATG), Brussels, Belgium, University Hospital, Ghent, University Ghent, Oslo University Hospital, Charite University, Berlin, Germany, Institut Pasteur, University of Aarhus, IrsiCaixa, Fundació Lluita contra les Infeccions, IRCCS San Raffaele, Imperial College London, University of Oxford, Guy's and St Thomas' NHS Foundation Trust, Chelsea and Westminster NHS Foundation Trust, Pomeranian Medical University Szczecin, Hospital Universitari Vall d'Hebron Research Institute, Medical University of Warsaw, Centre Hospitalier Universitaire Vaudois
Conditions	HIV
Enrollment	200 participants
Start Date	2026-10
Primary Completion	2027-10 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-09